Sign In
Buy ACXP
$1.75
-0.0500 (-2.78%)
At Close: Jun 03, 2026
Acurx Pharmaceuticals (NASDAQ:ACXP) Coverage Initiated at Maxim Group
09:12am, Friday, 03'rd Dec 2021 Transcript Daily
Maxim Group started coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating and a $12.00 target price on the stock. Acurx Pharmaceuticals stock opened at $4.22 on Monday. The businesss 50-day simple moving average is $4.91. Acurx Pharmaceuticals []
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Buys $24,979.24 in Stock
03:14pm, Thursday, 25'th Nov 2021 Dakota Financial News
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Carl Sailer acquired 5,161 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was purchased at an average price of $4.84 per share, for a total transaction of $24,979.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is […]
David P. Luci Buys 5,200 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock
10:14am, Wednesday, 24'th Nov 2021 Transcript Daily
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci bought 5,200 shares of the firms stock in a transaction that occurred on Friday, November 19th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $24,960.00. The transaction was disclosed in a legal filing with the SEC, which is []
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Increases By 17.7%
06:24am, Tuesday, 23'rd Nov 2021 Transcript Daily
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a large increase in short interest in the month of October. As of October 29th, there was short interest totalling 119,800 shares, an increase of 17.7% from the October 14th total of 101,800 shares. Based on an average daily volume of 72,400 shares, the days-to-cover ratio is currently 1.7 days. […]
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript
04:46pm, Monday, 15'th Nov 2021 Seeking AlphaAcurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript
11:46am, Monday, 15'th Nov 2021
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript
Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update
08:01am, Wednesday, 27'th Oct 2021
STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
09:00am, Monday, 04'th Oct 2021
STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ:
New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
01:40am, Friday, 27'th Aug 2021
New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
08:00am, Thursday, 12'th Aug 2021
STATEN ISLAND, N.Y. , Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update
08:00am, Wednesday, 28'th Jul 2021
STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference
08:00am, Thursday, 01'st Jul 2021
STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic
STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diff
